resveratrol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases alanine aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The comparison between RV group and placebo group shows a significant decrease in NH4 (p < 0.001) in AST (p < 0.001) and in ALT (p < 0.001) (Table 2).”
Quoted verbatim from Resveratrol in Patients with Minimal Hepatic Encephalopathy.. - Study
- RCT
- Duration
- 3 months
- Dose
- resveratrol pills 19.8 mg (Resvis) plus N-acetyl cysteine 600 mg and lactoferrin, versus placebo plus the same N-acetyl cysteine and lactoferrin, for 90 days
- Population
- Adults aged 25-65 with cirrhosis and minimal hepatic encephalopathy; N-acetyl cysteine 600 mg and lactoferrin given in both arms
Resveratrol in Patients with Minimal Hepatic Encephalopathy.2018PMID:29522439Permalink
Keep reading
- Everything the graph holds on resveratrol
- Every compound studied against Alanine aminotransferase
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M5RXZXZSX5YRKVFMDCHGA30P